Champions Oncology price target lowered to $7.50 from $9.00 at Roth MKM

Roth MKM lowered the firm’s price target on Champions Oncology to $7.50 from $9.00 but keeps a Buy rating on the shares after its Q1 results. The macro environment for early stage biotech remains challenging, and the company’s lead target unit is unproven at this point, the analyst tells investors in a research note. Longer term, Roth MKM remains positive on Champions Oncology’s base business of enhancing drug development with its library of altered mice, the firm added.